Pembrolizumab Provides Durable Survival Benefit in Metastatic Non-Small Cell Lung Cancer With High PD-L1 Expression
The 5-year survival rate was superior with pembrolizumab.
Non-Small Cell Lung Cancer
Sotorasib Produced Clinical Benefit in KRAS p.G12C-Mutated Non-Small Cell Lung Cancer
The median duration of response was 11.1 months.
Osimertinib Combinations as Second-Line Treatment in Non-Small Cell Lung Cancer: The Jury’s Still Out
Results from the BOOSTER trial add to data suggesting no benefit with osimertinib in combination over osimertinib alone.
Smoking History May Predict Immune Checkpoint Inhibitor Outcomes in Metastatic Non-Small Cell Lung Cancer
A detailed smoking history may help to inform patient outcomes.
Combining Durvalumab, Stereotactic Body Radiotherapy Could Hold Promise in Treatment of NSCLC
Researchers sought to determine the effect this regimen on outcomes for patients with early-stage non-small cell lung cancer.
PD-L1 Expression in Macrophage-Like Cells Linked to PFS After Immunotherapy in Non-Small Cell Lung Cancer
The size of cancer-associated macrophage-like cells was linked to progression-free survival as well.
Radiotherapy and Surgery Produce Comparable Outcomes in Operable Stage IA Non-Small Cell Lung Cancer
Survival results were similar with stereotactic ablative radiotherapy and surgery.
Surgical Data Support Nivolumab Plus Chemotherapy for Resectable NSCLC
The neoadjuvant regimen showed higher rates of definitive surgery and minimally invasive approach.
Adding Chemotherapy to Immunotherapy Improves Survival in Advanced Non-Small Cell Lung Cancer
Progression-free and overall survival were superior in patients who received immunotherapy and chemotherapy.
Low-Grade Immune-Related Adverse Events Linked to Prolonged Survival in NSCLC
Patients who experienced immune-related adverse events had longer overall survival than those who did not in both the atezolizumab-containing and control arms.
- Loading...
Loading...
Next post in ASCO 2021
Loading... 
Loading...